Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Nurix Therapeutics, Inc. ( NRIX ) H.C. Wainwright 28th Annual Global Investment Conference September 14, 2026 1:00 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Robert Burns - H.C. Wainwright & Co, LLC, Research Division Presentation Robert Burns H.C. Wainwright & Co, LLC, Research Division Welcome to our next fireside chat. I'm Robert Burns, Managing Director and senior biotech analyst at H.C. Wainwright. I'm joined today by the CEO of Nurix, Arthur Sands. Arthur, thank you for joining us today. Arthur Sands CEO, President & Director Well, thanks for having us. Very happy to be here. Question-and-Answer Session Robert Burns H.C. Wainwright & Co, LLC, Research Division Awesome. So maybe let's just start from a high level. For investors who may be newer to the Nurix story, can you provide a brief overview of the company, the platform and your pipeline today? Arthur Sands CEO, President & Director Yes. So we're focused on targeted protein degradation, which is a new small molecule approach to actually removing protein targets, disease targets from the cells via the ubiquitin proteasome system. So removal, targeted removal of the protein, which gets a more thorough hit on the target compared to inhibition. So our lead program is BTK, a BTK degrader called bexobrutideg, recently just signed a great deal with Roche, which I'm sure we'll talk about for CLL, chronic lymphocytic leukemia and non-Hodgkin's lymphomas, where, again, we're removing the BTK protein, and we get a more thorough and deeper efficacy response, can address resistance mutations to inhibitors. The inhibitor class is $10 billion a year class, but a lot of resistance mutations coming up. So degradation removes that with Bexdeg, as we call it for short. And then we have a whole inflammation program, partially with Bexdeg, again, with Roche, but also our STAT6 program with